20 percent of Rx-only digital therapeutics have studies so far.

Issue 065.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Teladongo, no bids for Proteus, and a pretty lengthy list of digital health-related CPT codes that the AMA's editorial panel is set to consider in October. Here's what's happening this week:

I'm working on a long-form report focused on Evidation Health. Any insights, metrics, rumors you can share? What would you like to better understand about Evidation? Hit reply to send me tips and questions.
Also, last week -- about an hour after I send the newsletter -- the AMA broke the link to its list of potential CPT codes. Here's a working link, which they updated seemingly because of a copy-paste error. (This new URL will likely break once they make an edit in September since -- mindbogglingly -- their URLs use a numeral to denote the month.)
The Lazarus of Digital

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

20 percent of Rx-only digital therapeutics have studies so far.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.